Capsule sponge tests move closer to routine use in oesophageal cancer detection

NICE has opened the door to wider use of capsule sponge tests for people at higher risk of oesophageal cancer, publishing draft guidance that supports Cytosponge and EndoSign for adults with persistent gastro-oesophageal reflux disease and for selected patients already known to have Barrett’s oesophagus. The decision matters because endoscopy capacity remains stretched, while the clinical need to identify precancerous change before invasive cancer develops remains stubbornly high.

The appeal of the tests is straightforward. A person swallows a small capsule attached to a thread; the capsule dissolves, a sponge expands in the stomach, and a clinician gently retrieves it to collect cells from the lining of the oesophagus. The entire process takes about seven minutes. In practical terms, that turns a hospital-based invasive investigation into a procedure that can be delivered in primary care facilities and community diagnostic centres, without sedation.

Early detection is the clinical logic behind the recommendation. Barrett’s oesophagus develops when the cells lining the lower oesophagus change, usually in the setting of long-term acid reflux. Most people with Barrett’s oesophagus will never develop cancer, but the condition increases risk, and oesophageal cancer becomes much harder to treat once it is found late. Detecting cellular change sooner allows triage toward endoscopy and treatment before disease advances beyond the point where local therapy is still possible.

A pathway designed to ease pressure on endoscopy services

The draft guidance covers two main uses. In adults with persistent GORD and multiple risk factors who do not need an urgent suspected cancer referral, Cytosponge and EndoSign can be considered to look for Barrett’s oesophagus or oesophageal cancer. For people already diagnosed with Barrett’s oesophagus, the same technologies can be used within a structured surveillance programme to look for cellular change that may signal progression.

Demand for endoscopy remains high, and in some parts of the NHS people with Barrett’s oesophagus are not being checked as often as current guidance recommends. That gap creates a simple but serious problem: when surveillance is delayed, abnormal change can go undetected until symptoms or disease progression force a later diagnosis. A faster, less invasive test gives services a way to expand screening and surveillance without sending every patient straight to a resource-intensive endoscopy slot.

One sentence captures the operational value: a single trained healthcare professional can administer the capsule sponge test, whereas endoscopy requires at least two nurses and an endoscopist.

The technology also appears acceptable to patients who would otherwise be referred for endoscopy. NICE’s committee found that many people prefer capsule sponge testing because it is quicker, less invasive, and avoids some of the more serious risks associated with endoscopy, including bleeding, damage to the oesophagus, and complications from sedation. Temporary throat discomfort can occur, along with soreness or mild irritation after the sponge is removed, but serious side effects are rare.

Why Barrett’s oesophagus is the critical target

Barrett’s oesophagus sits at the center of this recommendation because it is the lesion that links chronic reflux to cancer risk. Persistent reflux exposes the distal oesophagus to acid injury over time, and the tissue adapts by changing its cellular lining. That altered lining can later progress through dysplasia toward adenocarcinoma in a minority of patients, which is why surveillance has value even though most people never advance to cancer.

The test’s purpose is not to replace endoscopy altogether. It is designed to identify the patients who most need it. A positive capsule sponge result points toward further investigation, with endoscopy used to confirm findings and guide next steps. A negative result does not close the case permanently, because no diagnostic test identifies every cancer or every case of Barrett’s oesophagus. Patients with negative findings still need clear advice on when to seek further help if symptoms change or persist.

NICE’s committee also examined the practical gains beyond patient comfort. Around 95 out of every 100 people are able to swallow the capsule successfully after one or more attempts, which makes the procedure workable at scale. Research support from the National Institute for Health and Care Research, including the earlier BEST3 trial and the £7.6 million BEST4 screening trial, helped build the evidence base for moving the technology into wider consideration.

National HealthTech Access Programme sets the policy frame

The draft recommendation is the first to emerge from the National HealthTech Access Programme, a new route intended to identify high-impact medical devices, diagnostic tests and digital technologies that could be adopted consistently across the NHS if recommended by NICE. The programme brings NICE together with the Department of Health and Social Care, NHS England, the Medicines and Healthcare products Regulatory Agency and the Office for Life Sciences.

The policy goal is as much about equity as it is about innovation. If final guidance recommends these tests, eligible patients in England should be able to access them wherever they live rather than depending on local commissioning decisions or uneven service availability. For a diagnostic pathway, that consistency matters. Cancer detection cannot depend on geography, especially when late diagnosis is one of the main reasons outcomes remain poor.

Professor Jonathan Benger, chief executive of NICE, said the first technology to be considered through the programme represents an important step toward consistent adoption across the NHS. Professor Peter Johnson, national clinical director for cancer at NHS England, pointed to the growing number of patients with acid reflux and the prospect of easier access to testing that can reduce the need for more complicated endoscopy while helping the NHS find cancers earlier.

Consultation, surveillance updates, and the next decision point

The draft guidance is open for comment until 7 December 2026. NICE’s committee will review consultation responses on 16 December 2026 before final recommendations are issued for appeal in January 2027. If final guidance is confirmed in February 2027, the NHS in England will be required to begin delivery within the clinical pathway, including specialist staff training, when capsule sponge testing is considered the most suitable option.

One unresolved issue sits in the background: NICE is also updating its guideline on Barrett’s oesophagus and stage 1 oesophageal adenocarcinoma, and the capsule sponge guidance will be reviewed if surveillance recommendations change. The long-term place of the test will therefore depend on how the full pathway is written, not just on whether the device itself performs well.

For now, the central clinical question is narrow and concrete: can a short, office-based test safely widen access to Barrett’s oesophagus detection while preserving endoscopy for patients most likely to benefit from it? The draft guidance says yes, but the final answer will rest on the consultation process and the shape of the updated surveillance pathway.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by NICE (UK) Guidance.